Interestingly, celastrol is reported to inhibit the activation of the NLRP3 inflammasome in LPS-induced liver damage and monosodium urate-induced gouty arthritis by blocking the de-ubiquitination of NLRP3 and cleavage of pro-IL-1β, without affecting the total protein level of NLRP3 [71]. Here, NLRP3 is linked to gout.